Skip to main navigation Skip to search Skip to main content

Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study

Research output: Contribution to journalJournal articlepeer-review

Original languageKorean
JournalARTHRITIS RESEARCH & THERAPY
StatePublished - 2019.05.21

Cite this